JAC Advance Access published online on August 13, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg371
© 2003 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brief report
1 Division of Respiratory Diseases, Department of Medicine,
Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama
701-0192, Japan
* Corresponding author. E-mail: nao{at}med.kawasaki-m.ac.jp.
Received 14 February 2003
; revised 13 June 2003
; accepted 17 June 2003
Objectives: To investigate the in
vitro activity of cethromycin, a new ketolide, against Chlamydia pneumoniae. Methods: The in vitro activity
of cethromycin against 20 isolates of C. pneumoniae was compared
with the activities of telithromycin, erythromycin A, azithromycin
and clarithromycin against those isolates. Results: The MIC at which 90% of the
isolates were inhibited and the minimal chlamydiacidal concentration at
which 90% of the isolates were killed by cethromycin were
both 0.016 mg/L (range 0.016-0.031 mg/L). Cethromycin was
the most active antibiotic tested in this study. Conclusions: Our results appear to indicate
that cethromycin is an effective antibiotic that should play some role
in the treatment of respiratory tract infections caused by C.
pneumoniae.
Keywords: macrolides, telithromycin, community-acquired
pneumonia
In vitro activity of cethromycin,
a novel antibacterial ketolide, against Chlamydia pneumoniae
![]()
CiteULike
Connotea
Del.icio.us What's this?